0001437749-15-021355.txt : 20151223 0001437749-15-021355.hdr.sgml : 20151223 20151123165620 ACCESSION NUMBER: 0001437749-15-021355 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20151123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CESCA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: THERMOGENESIS CORP DATE OF NAME CHANGE: 19951117 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm kool20151123_corresp.htm

CESCA THERAPEUTICS INC.

2711 CITRUS ROAD

RANCHO CORDOVA, CALIFORNIA 95742

 

November 23, 2015

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention:

Amanda Ravitz, Assistant Director

   
Re:         Cesca Therapeutics Inc.
  Registration Statement on Form S-1 (No. 333-207115)
  Request for Acceleration                                                     

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cesca Therapeutics Inc. (the "Company"), hereby requests that the effective date of its Registration Statement on Form S-1 (File No. 333-207115) be accelerated so that the same will become effective at 10:00 a.m., Eastern Time, on Tuesday, November 24, 2015 or as soon thereafter as practicable.

 

The Company hereby acknowledges the following:

 

(i)      should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

(ii)     the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

(iii)    the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

If you have any questions regarding this request or the Registration Statement, please call our counsel Taylor Bentley, of Weintraub Tobin, at (916) 558-6129.

 

 

Very truly yours,

 

  Cesca Therapeutics Inc.  

 

 

 

 

 

By:

/s/ Robin C. Stracey

 

 

Robin C. Stracey

 

 

Chief Executive Officer